Matthew L. Posard

Matthew L. Posard is a declared insider at 3 companies (senior executive); the most frequent names are Halozyme Therapeutics, Inc., DermTech, Inc. and Nautilus Biotechnology, Inc. Between 5 May 2021 and 1 October 2026, the trades on record add up to 20 filings.

The open-market side counts 1 purchase for €81k alongside 11 sales for €3.8M. The net balance comes to €3.7M on the selling side. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Other entries cover 8 share grants. So far in 2026, the count stands at no purchases and 8 sales.

The record was last updated on 2 October 2026 with an open-market sale (€106k) in Halozyme Therapeutics, Inc. The clock since the last published purchase (1 December 2021) now reads 1,782 days. Typically, a trade is published a median of 1 day after it takes place. US insiders must file a Form 4 within two business days of a trade. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.